Search results
-
ASCO 2024 – AbbVie sees SEZ6 improvement
ASCO 2024 – AbbVie sees SEZ6 improvement …
- 06/03/2024 - 19:15 -
ASCO 2024 – Blenrep “should return” to the US
ASCO 2024 – Blenrep “should return” to the US …
- 06/03/2024 - 01:15 -
ASCO 2024 – Enhertu nears its “ultralow” dream
ASCO 2024 – Enhertu nears its “ultralow” dream …
- 06/03/2024 - 21:09 -
ASCO 2024 – some Adriatic fears allayed
ASCO 2024 – some Adriatic fears allayed …
- 06/02/2024 - 15:21 -
ASCO 2024 – Laura’s crossover conundrum
ASCO 2024 – Laura’s crossover conundrum …
- 06/02/2024 - 15:20 -
ASCO 2024 – Krazati looks more similar than different to Lumakras
ASCO 2024 – Krazati looks more similar than different to … events 47% 46% 33% 40% Source: ASCO 2024 & Oncology Pipeline. Codebreak-200 …
- 06/02/2024 - 15:19 -
ASCO 2024 – new matching strategy delays Caribou
ASCO 2024 – new matching strategy delays Caribou … The evolving Antler dataset ASCO 2024 Jul 2023 update Cutoff 1 Apr 2024 … 76% 94% CR rate 46% 69% Source: ASCO 2024 & OncologyPipeline. Results were …
- 06/03/2024 - 21:12 -
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
ASCO 2024 – full Evoke-01 result adds to Gilead’s … and a secondary endpoint in Evoke-01. Source: ESMO 2023 & ASCO 2024. Conferences Trial …
- 06/01/2024 - 22:08 -
ASCO 2024 – Summit peaks on ivonescimab surprise
ASCO 2024 – Summit peaks on ivonescimab surprise … OS Immature 21.1mth 19.2mth Source: ASCO 2024 & OncologyPipeline. Overall survival …
- 06/02/2024 - 15:03 -
ASCO 2024 – J&J flies towards a more convenient Rybrevant
ASCO 2024 – J&J flies towards a more convenient Rybrevant … non-inferiority criteria; **trend in favour of SC. Source: ASCO 2024. When asked for a potential explanation …
- 06/01/2024 - 01:41
